Proteon Therapeutics, Inc. (NASDAQ:PRTO) produced a 22.86% rally since recording the worst price of $0.35. Thanks to the latest -4.44% decrease, it now trades at $0.43. Throughout the trading on 6/5/2019, the share price floated between $0.4085 and $0.532. This company shares are 132.56% off its target price of $1 and the current market capitalization stands at $8.77M. The recent change has given its price a -32.53% deficit over SMA 50 and -89.09% deficit over its 52-week high. The stock witnessed 1.27% gains, -88.12% declines and -74.1% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found PRTO’s volatility during a week at 16.12% and during a month it has been found around 16.07%.

Proteon Therapeutics, Inc. (PRTO) Top Holders

Institutional investors currently hold around $3 million or 45.6% in PRTO stock. Look at its top three institutional owners: Abingworth Llp owns $908 thousand in Proteon Therapeutics, Inc., which represents roughly 10.35% of the company’s market cap and approximately 30.27% of the institutional ownership. Similar statistics are true for the second largest owner, Pharmstandard International S.A., which owns 1,607,807 shares of the stock are valued at $724 thousand. The third largest holder is Deerfield Management Company, L.P. (Series C), which currently holds $551 thousand worth of this stock and that ownership represents nearly 6.28% of its market capitalization.

Proteon Therapeutics, Inc. 13F Filings

At the end of March reporting period, 6 institutional holders increased their position in Proteon Therapeutics, Inc. (NASDAQ:PRTO) by some 280,124 shares, 18 decreased positions by 4,436,664 and 7 held positions by 1,367,061. That puts total institutional holdings at 6,083,849 shares, according to SEC filings. The stock grabbed 3 new institutional investments totaling 121,309 shares while 17 institutional investors sold out their entire positions totaling 4,403,513 shares.

Proteon Therapeutics, Inc. (NASDAQ:PRTO) Insider Trades

Multiple company employees have indulged in significant insider trading. Proteon Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that SVP and Chief Medical Officer Burke Steven Keith has acquired 12,000 shares of Proteon Therapeutics, Inc. (PRTO) in the trading session dated Dec. 15, 2017. These shares are worth $22,560 and were traded at $1.88 each. The SEC filing shows that Flynn James E performed a sale of 110,557 shares. The disposed these shares by way of transaction on Nov. 30, 2017. The company’s shares were given away at $1.75 per share worth to an income of some $193,475 to the account of Flynn James E.

, Flynn James E, purchased 110,557 common shares of Proteon Therapeutics, Inc. (PRTO) in the open market. In a transaction dated Nov. 30, 2017, the shares were bought at an average price of $1.75, giving away a sum of $193,475. After this purchase, 1,224,899 common shares of PRTO are directly owned by the insider, with total stake valued at $526,707.

In the transaction dated Nov. 14, 2017, a great number of shares acquired came courtesy the Sr VP, CFO, Treasr, Asst Secy; Eldridge, George Arthur added a total of 295 shares at an average price of $1.69, amounting to approximately $499. The insider now directly owns 14,295 shares worth $6,147.

Proteon Therapeutics, Inc. (PRTO) Analyst Guide

Several analysts have released their opinion on Proteon Therapeutics, Inc. (NASDAQ:PRTO), with 0 analysts believing it is a strong buy. Whereas 3 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 3 average brokerage recommendation [T1].